<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210119/" ref="ordinalpos=4555&amp;ncbi_uid=3403671&amp;link_uid=PMC3210119" image-link="/pmc/articles/PMC3210119/figure/pone-0025507-g002/" class="imagepopup">Figure 2. C225-NP regulates EGFR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> in tumor cells but not in normal cells..  From: EGFR-Targeted Hybrid Plasmonic Magnetic Nanoparticles Synergistically Induce Autophagy and Apoptosis in Non-Small Cell Lung Cancer Cells. </a></div><br /><div class="p4l_captionBody">Inhibitory effects of C225-NP on phosphorylated EGFR and the downstream signaling molecules in human lung cancer and normal cells. C225-NP treatment reduced the expression of phosphorylated (p) forms of EGFR, AKT, p38 MAPK, and P44/42 MAPK in EGFR-positive tumor cells but not in normal cells. There was no effect on EGFR-null H520 tumor cells.</div></div>